Apotex Wins 2nd Generic Ozempic Approval in Canada
Health Canada has cleared a second generic semaglutide — this one made in Canada by Apotex — accelerating the price collapse expected to ripple across benefit plans.
May 8, 2026 · 2 min read
Canada now has a second generic semaglutide. Health Canada has approved an Apotex-manufactured version of injectable semaglutide following the late-April approval of Dr. Reddy's, marking the first major economy with multiple legitimate generic versions of Ozempic on the market. For Canadian patients and benefit plans, the second approval is the trigger for materially lower prices.
What happened
Apotex's approval makes Canada the only major market with two interchangeable generic semaglutide products simultaneously available. The country reached this position because Novo Nordisk's foundational semaglutide patent lapsed years ago — Canadian press reports have linked this to a missed patent maintenance fee in 2020 — and the eight-year regulatory data exclusivity window expired in early January 2026. A secondary patent on the injectable formulation expired in March.
Pricing follows the standard pan-Canadian generic pricing schedule. With one generic on market, prices typically settle at 75–85% of brand. With a second generic, both drop to roughly half of brand. With three or more, generic pricing falls toward 35% of brand. The Apotex approval moves Canada into the second tier and sets up further drops if additional manufacturers reach the market this year.
Why it matters
Canada is the test case the rest of the world will watch. Brand semaglutide retails north of $1,000 USD/month in many markets without insurance. The first generation of legitimate Canadian generics could approximately halve that for cash payers, with deeper cuts as the market thickens.
For private benefit plans, the transition is less straightforward than it sounds. Most plans automatically substitute generics once they're available, but uneven uptake and active negotiation between plans, manufacturers, and pharmacy benefit managers can slow the savings reaching the plan sponsor. Initial commentary from Canadian benefits analysts has flagged that the realized cost reduction will depend on plan design and existing rebate arrangements with Novo Nordisk.
For US patients, this is mostly a forward indicator rather than immediate relief — semaglutide's primary US patents don't expire until later this decade. But it sets a price floor the rest of the market can point to. For background on how compounded semaglutide already changed the US affordability picture, see our compounded semaglutide safety cluster.
What to watch
The next inflection points: how quickly private plans and provincial drug plans add the generics to formularies, whether additional manufacturers (the queue is reportedly long) clear approval through the rest of 2026, and whether Novo Nordisk responds with brand-side discounting to defend share. The Apotex approval also strengthens cross-border conversations in the US, where generic semaglutide remains years away.
Sources
Sources